Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 17, 2021 - Issue 12
Submit an article Journal homepage
585
Views
0
CrossRef citations to date
0
Altmetric
Letters

Immune variants of SARS-CoV-2 could be a significant challenge for developing a pan genotype-specific vaccine

Abhay SinghDepartment of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, IndiaView further author information
&
Sachin KumarDepartment of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, IndiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8526-6013View further author information
ORCID Icon
Pages 5145-5147 | Received 10 Aug 2021, Accepted 22 Oct 2021, Published online: 02 Dec 2021

References

  • Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, Hasell J, MacDonald B, Beltekian D, Dattani S, et al. Coronavirus pandemic (COVID-19). Our World in Data. 2020.
  • European Centre for Disease Prevention and Control, 11 May . Emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA https://www.ecdc.europa.eu/sites/default/files/documents/Emergence-of-SARS-CoV-2-B.1.617-variants-in-India-and-situation-in-the-EUEEA_0.pdf. 2021.
  • Winger A, Caspari T. The spike of concern-the novel variants of SARS-CoV-2. Viruses. 2021;13:1002. doi:10.3390/v13061002.
  • Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L, et al. The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell. 2020;182(5):1284–94 e9. doi:10.1016/j.cell.2020.07.012.
  • Johnson BA, Xie X, Kalveram B, Lokugamage KG, Muruato A, Zou J, Zhang X, Juelich T, Smith JK, Zhang L, et al. Furin cleavage site is key to SARS-CoV-2 pathogenesis. bioRxiv. 2020.
  • Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385:385–94.
  • Sheikh A, McMenamin J, Taylor B, Robertson C; Public Health S, The EIIC. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021;397(10293):2461–62. doi:10.1016/S0140-6736(21)01358-1.
  • England PH. SARS-CoV-2 variants of concern and variants under investigation in England. London: Public Health England; 2021.
  • Wadman Meredith 29 January 2021 . Novavax vaccine delivers 89% efficacy against COVID-19 in U.K.—but is less potent in South Africa. Science. 2021; doi:10.1126/science.abg8101.
  • Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MSL, Moodley D, Hanley S, et al. Efficacy of NVX-CoV2373 COVID-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1899–909. doi:10.1056/NEJMoa2103055.
  • Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. 2021;384(23):2187–201. doi:10.1056/NEJMoa2101544.
  • Jongeneelen M, Kaszas K, Veldman D, Huizingh J, van der Vlugt R, Schouten T, Zuijdgeest D, Uil T, van Roey G, Guimera N, et al. Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern. bioRxiv. 2021.
  • Moderna. Moderna provides a clinical update on the neutralizing activity of its COVID-19 vaccine on emerging variants including the Delta variant first identified in India. 2021.
  • Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, Tang P, Hasan MR, Malek JA, Coyle P, Ayoub HH, Al Kanaani Z, et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat Med. 2021;27(9):1614–21. doi:10.1038/s41591-021-01446-y.
  • Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, Porrot F, Robillard N, Puech J, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276–80. doi:10.1038/s41586-021-03777-9.
  • Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, Aileni VK, Kanungo S, Rai S, Reddy P, et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. medRxiv. 2021.
  • Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, Mizrahi B, Alroy-Preis S, Ash N, Milo R, et al. Protection of BNT162b2 vaccine booster against COVID-19 in Israel. N Engl J Med. 2021;385(15):1393–400. doi:10.1056/NEJMoa2114255.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.